Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.120
+0.010 (0.89%)
At close: Dec 5, 2025, 4:00 PM EST
1.140
+0.020 (1.79%)
After-hours: Dec 5, 2025, 7:59 PM EST
Company Description
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
| Phone | (908) 967-6677 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| Employer ID | 99-4362660 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chief Executive Officer, President and Executive Chairman |
| Myron Z. Holubiak | Secretary and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Financial Officer and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Oct 27, 2025 | 8-K | Current Report |
| Oct 23, 2025 | 8-K | Current Report |
| Sep 26, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 19, 2025 | 8-K | Current Report |
| Sep 12, 2025 | SCHEDULE 13D/A | Filing |
| Sep 10, 2025 | 424B3 | Prospectus |
| Sep 10, 2025 | 8-K | Current Report |